GlassScriptPhysician profile
Doosup Shin
NPI 1538517909
$64,935.08
in general payments reported to CMS, 2019-2025
15 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.97 · 2021: $321 · 2022: $3,374 · 2023: $52K · 2024: $8,160 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $52K · Travel and Lodging: $6,286 · Food and Beverage: $3,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $51,575.09 |
| Travel and Lodging | $6,285.82 |
| Food and Beverage | $3,361.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41,694.57 | 2021-2025 | Optis, Coroflow, Xience Skypoint |
| Medtronic, INC. | $17,754.68 | 2023-2025 | Resolute Onyx, Symplicity G3, Corevalve Evolut R |
| Boston Scientific Corporation | $3,103.36 | 2022-2024 | Avvigo Guidance System |
| Recor Medical INC | $1,267.16 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Shockwave Medical, INC | $281.16 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $166.13 | 2020-2025 | |
| Cardiovascular Systems INC. | $148.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $130.62 | 2021-2022 | |
| Chiesi USA, INC. | $96.25 | 2022-2025 | Kengreal, Cleviprex |
| Cardiva Medical, INC. | $69.91 | 2025 | Cardiva Vascade 5f Vcs, Cardiva Vascade 6/7f Vcs |
| Biotronik INC. | $68.86 | 2021-2024 | Recross |
| Zoll Circulation INC | $56.98 | 2023 | Catheter, Temperature Management System, Temperature Management System Start-Up Kit |
| Amgen INC. | $56.65 | 2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $23.84 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $16.91 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doosup Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.